© 2020 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Oncology
Overcoming Cancer’s Financial Toxicity with Real-World Data
September 15, 2020
Financial Toxicity is a growing concern for many cancer patients and caregivers, and with the continued rise in treatment costs, it can no longer be ignored.
FDA Updates: Treatment for Duchenne Mutation, Gilead Seeks Remdesivir Approval, Data on ALKS 3831
August 16, 2020
Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.
FDA Updates: Assays Used in Cancer Care Get Green Light
August 09, 2020
Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.
Racial Disparities in Cancer Enter the Spotlight
July 29, 2020
Underrepresentation of blacks in clinical trials is garnering special attention.
It's Possible for Those Who Practice, Pay for Precision Oncology to Catch Up to Speed of Innovation
July 14, 2020
The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 01, 2020
In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Keytruda Approved for Early Treatment of Colorectal Cancer in Patients With Genetic Mutations
June 30, 2020
FDA approves Merck's Keytruda for certain patients with metastatic colorectal cancer a month after study results were presented at ASCO.
5 Developments Changing the CAR-T Landscape
June 28, 2020
An off-the-shelf version of CAR-T therapy that uses the immune system’s natural killer cells is a possibility. But the high price of CAR-T shows some doubts about how widely it can be used.
Flatiron Health's Bobby Green Outlines Cancer Clinical Trial to Understand Genomic Changes in Tumors (Pt. 4)
June 22, 2020
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Flatiron Health’s Dr. Bobby Green Outlines Novel Clinical Trial to Understand Genomic Changes in Tumors (pt. 2) (VIDEO)
June 06, 2020
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials.
Kathi Mooney of Huntsman Cancer Institute Speaks on Hospital-at-Home Programs
June 03, 2020
Kathi Mooney, Ph.D., RN, FAAN, interim senior director of population sciences at the Huntsman Cancer Institute in Salt Lake City, discusses hospital-at-home programs and how they are common in countries with single-payer systems and include patients with conditions ranging from cellulitis to heart failure. The benefits include the familiarity of home surroundings, avoidance of hospital-acquired infection, and less de-conditioning from being in a hospital bed.
Jeffrey Skolnik of Inovio Pharmaceuticals Inc. Discusses Glioblastoma Treatment
June 02, 2020
Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.
AstraZeneca's Adrian Kilcoyne Claims Paradigm Shift in Lung Cancer Treatment
June 02, 2020
Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.
AstraZeneca’s Tagrisso Keeps Most Lung Cancer Patients With Mutation Alive Two Years After Surgery
June 01, 2020
Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.
Keytruda Doubles Progression-Free Survival for Colorectal Cancer Patients with Mutation
June 01, 2020
Keytruda, the immunotherapy with more than 20 indications in both blood and solid tumor cancers, doubled rates of progression-free survival for certain patients with metastatic colorectal cancer, according to results presented Sunday at the American Society of Clinical Oncology annual meeting.